Anavex Life Sciences Corp (AVXL)

[wildcard235]

Not at $15 due to:

1. It's start on the pink sheets.
2. The first management team running out of operating funds. (Pre-Dr. Missling)
3. It's prior Short & Distort attacks scaring off headline/twit investors who don't even know what due diligence is.

All of which is irrelevant in the long-term. When FDA approval is granted, AVXL becomes a life-saver for patients and a gold-mine for early investors.